<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05105867</url>
  </required_header>
  <id_info>
    <org_study_id>GC502-411</org_study_id>
    <nct_id>NCT05105867</nct_id>
  </id_info>
  <brief_title>CD19 Targeted UCAR-T for CD19+ Refractory/Relapsed B-ALL/NHL</brief_title>
  <official_title>Anti-CD19 Universal CAR-T Cells for CD19+ Refractory/Relapsed B Cell Acute Lymphoblastic Leukemia and Refractory/Relapsed B Cell Non-hodgkin's Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>920th Hospital of Joint Logistics Support Force of People's Liberation Army of China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gracell Biotechnology Shanghai Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>920th Hospital of Joint Logistics Support Force of People's Liberation Army of China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single arm, open-label, multi-center prospective study to determine the safety and&#xD;
      efficacy of CD19 UCAR-T cells in patients diagnosed with CD19+ refractory/relapsed B cell&#xD;
      acute lymphoblastic leukemia and B cell non-Hodgkin lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity</measure>
    <time_frame>Up to 4 weeks after CAR-T infusion</time_frame>
    <description>CRS lasting ≥7 days G3 or ≥G4 after CAR-T infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AE after CAR-T infusion</measure>
    <time_frame>B-ALL up to 12 weeks and B-NHL up to 24 weeks after CAR-T infusion</time_frame>
    <description>Incidence of adverse events after CAR-T infusion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR rate</measure>
    <time_frame>4 weeks，12 weeks, 24 weeks after CAR-T infusion</time_frame>
    <description>Overall response rate after CAR-T infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>4 weeks，12 weeks, 24 weeks after CAR-T infusion</time_frame>
    <description>Progression free survival after CAR-T infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>4 weeks，12 weeks, 24 weeks after CAR-T infusion</time_frame>
    <description>overall survival after CAR-T infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CAR Copies</measure>
    <time_frame>B-ALL up to 12 weeks and B-NHL up to 24 weeks after CAR-T infusion</time_frame>
    <description>CAR Copies measured by qPCR after CAR-T infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of CAR-T cell counts</measure>
    <time_frame>B-ALL up to 12 weeks and B-NHL up to 24 weeks after CAR-T infusio</time_frame>
    <description>CAR-T cell counts measured by Flow cytometry after CAR-T infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the concentration of cytokine</measure>
    <time_frame>Up to 4 weeks after CAR-T infusion</time_frame>
    <description>Cytokines in serum measured by ELISA after CAR-T infusion</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>anti-CD19 UCAR-T treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anti-CD19 UCAR-T is an allogeneic CAR-T. A single infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-CD19 UCAR-T injection</intervention_name>
    <description>After preconditioning with chemotherapy ( Flu+ Cy), the dosage of anti-CD19 UCAR-T cells between 0.5 and 2 ×10^7 cells/Kg will be evaluated.</description>
    <arm_group_label>anti-CD19 UCAR-T treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern cooperative oncology group (ECOG) performance status of 0 to 1；&#xD;
&#xD;
          2. Life expectancy ≥12 weeks;&#xD;
&#xD;
          3. Quantifiable tumor burden;&#xD;
&#xD;
          4. Understand and voluntarily sign the informed consent form.&#xD;
&#xD;
          5. Confirmed diagnosis of CD19+ relapsed/refractory B-ALL or B-NHL;&#xD;
&#xD;
          6. Adequate hematological, renal and liver function;&#xD;
&#xD;
          7. Female of childbearing age must agree to take effective contraceptive measures at&#xD;
             least 1 year after infusion; Male with fertile partners must agree to use effective&#xD;
             barrier contraceptive methods at least 1 year after infusion;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of other malignancy (except for cured non-melanoma skin cancer, cervical&#xD;
             carcinoma in situ, superficial bladder cancer, ductal carcinoma in situ, or other&#xD;
             malignancies that have completely responsed for more than 5 years);&#xD;
&#xD;
          2. Severe mental disorders;&#xD;
&#xD;
          3. History of hereditary diseases, including but not limited to: Fanconi anemia, Shut-Dai&#xD;
             syndrome, Costman syndrome or any other known bone marrow failure syndrome;&#xD;
&#xD;
          4. History of grade 2-4 acute graft-versus-host disease (GVHD) (Glucksberg criteria) or&#xD;
             extensive chronic GVHD (Seattle criteria);&#xD;
&#xD;
          5. Grade III-IV heart failure or myocardial infarction, angioplasty or stent placement,&#xD;
             unstableangina pectoris, or other clinically prominent heart disease within one year&#xD;
             before enrollment.&#xD;
&#xD;
          6. Subjects with CNS lymphoma, cerebrospinal fluid malignant cells or brain metastases.&#xD;
&#xD;
          7. History or presence of CNS disorder, including but not limited to: seizure disorder,&#xD;
             cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease, or any autoimmune&#xD;
             disease with CNS involvement;&#xD;
&#xD;
          8. Positive for any of the following etiological tests: HIV, HBV, HCV, TPPA;&#xD;
&#xD;
          9. There were active infections requiring systematic treatment in the 2 weeks prior to&#xD;
             screening;&#xD;
&#xD;
         10. Severe Allergic subjects or subjects with allergic reactions to cyclophosphamide or&#xD;
             fludarabine;&#xD;
&#xD;
         11. History of autoimmune disease resulting in end organ injury or requiring systemic&#xD;
             immunosuppression/systemic disease modifying agents within the last 2 years;&#xD;
&#xD;
         12. History or diagnosis of pulmonary fibrosis;&#xD;
&#xD;
         13. Subjects who received other clinical trial therapy within 4 weeks before participating&#xD;
             in this trial, or the informed consent form was signed within the 5 half-life of the&#xD;
             last administration in the other clinical trial (take longer time as standard);&#xD;
&#xD;
         14. Poor adherence due to physical, family, social, geographic, and other factors, who&#xD;
             cannot follow the research plan and follow-up plan;&#xD;
&#xD;
         15. Subjects with comorbidities that require systemic corticosteroid therapy (≥5 mg/day of&#xD;
             prednisone or an equivalent dose of other corticosteroids) or other immunosuppressive&#xD;
             drugs within 1 months after study therapy according to the discretion of investigator;&#xD;
&#xD;
         16. Donor lymphocyte infusion 6 weeks prior to enrollment;&#xD;
&#xD;
         17. Pregnant women and lactating women who are reluctant to stop breastfeeding;&#xD;
&#xD;
         18. Any other conditions defined by researcher that is inappropriate for the subject to be&#xD;
             enrolled;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sanbin Wang, Professor</last_name>
    <phone>13187424131</phone>
    <phone_ext>+86</phone_ext>
    <email>Sanbin1011@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>920th Hospital of Joint Logistics Support Force of People's Liberation Army of China</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanbin Wang, Professor</last_name>
      <phone>13187424131</phone>
      <phone_ext>+86</phone_ext>
      <email>Sanbin1011@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 25, 2021</study_first_submitted>
  <study_first_submitted_qc>October 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2021</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>920th Hospital of Joint Logistics Support Force of People's Liberation Army of China</investigator_affiliation>
    <investigator_full_name>Wang Sanbin</investigator_full_name>
    <investigator_title>Director of Hematology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

